Skip to main content

Marilyn Jo Telen

Wellcome Clinical Distinguished Professor of Medicine in Honor of R. Wayne Rundles, M.D.
Medicine, Hematology
Duke Box 2615, Durham, NC 27710
333 Med Sci Res Bldg, Durham, NC

Selected Grants


U2C/TL1 NC KUH TRIO Administrative Core

ResearchPreceptor · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028

Sickle Cell Disease Functional Assessment Validation and Exercise Pilot Intervention

ResearchMentor · Awarded by National Heart, Lung, and Blood Institute · 2023 - 2028

Staphylococcus aureus Cardiac Device Infections - From the Vascular Viewpoint (K23)

ResearchAdvisor · Awarded by National Institutes of Health · 2022 - 2027

Point of care diagnostic for sickle cell disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2026

U2C/TL1 NC KUH TRIO Administrative Core

ResearchPreceptor · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028

Sickle Cell Disease Functional Assessment Validation and Exercise Pilot Intervention

ResearchMentor · Awarded by National Heart, Lung, and Blood Institute · 2023 - 2028

Staphylococcus aureus Cardiac Device Infections - From the Vascular Viewpoint (K23)

ResearchAdvisor · Awarded by National Institutes of Health · 2022 - 2027

Point of care diagnostic for sickle cell disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2026

Hematology & Transfusion Medicine (T32)

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026

Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)

Clinical TrialPrincipal Investigator · Awarded by University of Maryland, Baltimore · 2022 - 2025

4202-HEM-201 Pro00109172

Clinical TrialPrincipal Investigator · Awarded by FORMA Therapeutics, Inc. · 2022 - 2024

Randomized double-blind study of FT-4202 in sickle cell disease

Clinical TrialPrincipal Investigator · Awarded by FORMA Therapeutics, Inc. · 2019 - 2024

Duke CTSA (TL1) Year 5

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024

Multi-site Clinical Laboratory Testing for SickleScan

Clinical TrialPrincipal Investigator · Awarded by BioMedomics, Inc. · 2017 - 2024

Identifying novel clinical, genetic and proteomic risk factors for sickle cell nephropathy.

ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2023

A Phase II trial of topical sodium nitrite in patients with sickle cell disease and leg ulcers Cost Reimbursable

Clinical TrialPrincipal Investigator · Awarded by Food and Drug Administration · 2017 - 2022

Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)

Clinical TrialPrincipal Investigator · Awarded by University of Pittsburgh · 2020 - 2022

Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)

Clinical TrialPrincipal Investigator · Awarded by University of Pittsburgh · 2020 - 2022

CSA - Pfizer 212511 B5201002 Phase 3 Randomized Multicenter Trial

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2015 - 2021

Patient Preference Information: Bridging Regulatory Decisions and Clinical Practice

ResearchPhysician · Awarded by Food and Drug Administration · 2018 - 2021

FORMA Therapeutics FT-4202

ResearchPrincipal Investigator · Awarded by FORMA Therapeutics, Inc. · 2019 - 2021

Sharing Comprehensive 'Omics in Sickle Cell Disease Through the NHLBI TOPMed Network

ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation, Inc. · 2019 - 2020

Transcriptomic, therapeutic and genetic investigations of sickle cell nephropathy

ResearchCo Investigator · Awarded by National Institutes of Health · 2016 - 2020

Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)

Clinical TrialPrincipal Investigator · Awarded by University of Pittsburgh · 2020 - 2020

High-throughput Metabolite Profiling and Genetic Analyses to Identify Novel Predictive Biomarkers of SCD-related Complications

ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation · 2015 - 2020

Duke-UNC Clinical Hematology and Transfusion Research Career Development Program

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2019

Use of Mobile Technology to Improve Acute Care Utilization in Sickle Cell Disease

ResearchCo Investigator · Awarded by Agency for Healthcare Research and Quality · 2015 - 2018

Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor)

FellowshipPrincipal Investigator · Awarded by Vanderbilt University · 2017 - 2018

Thalassemia Screening in Myanmese and Lao Migrants in Thailand

FellowshipPrincipal Investigator · Awarded by Cooley's Anemia Foundation · 2017 - 2018

Factor XIII and Fibrinogen: Mechanisms of Genetic Risk in SCD-Related Priapism

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2018

Improving Pain in Sickle Cell Patients With Targeted Antithrombotic Therapy

ResearchCo-Mentor · Awarded by National Institutes of Health · 2014 - 2017

PFIZER B0401016

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2015 - 2017

Role of RBC NO and ATP in Sickle Vasculopathy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2016

Extension of Hematologic & Clinical Genotype-Phenotype Associations in SCD Using Exome Chip & Metabolomic Analysis

ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation · 2013 - 2015

Instrumentation for Quantitative Phosphoproteomics and Acetylomics

EquipmentMajor User · Awarded by National Institutes of Health · 2014 - 2015

Lateral Flow Hemoglobinopathies Test Development

ResearchPrincipal Investigator · Awarded by BioMedomics, Inc. · 2014 - 2014

Impaired release of antiadhesive ATP from stored RBCs: a novel transfusion lesion

ResearchClinical Investigator · Awarded by National Institutes of Health · 2012 - 2014

Phase II Study of Propranolol as Anti-Adhesive Therapy in SCD

ResearchMentor · Awarded by National Institutes of Health · 2009 - 2013

PROPRANOLOL AS ANTI-ADHESIVE THERAPY IN SCD

Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2010 - 2012

Duke/UNC Comprehensive Sickle Cell Center

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2003 - 2012

Training in the Genome Sciences and the Hemoglobinopathies

Inst. Training Prgm or CMECo-Director · Awarded by National Institutes of Health · 2006 - 2012

Training in the Genome Sciences and the Hemoglobinopathies

Inst. Training Prgm or CMECo-Director · Awarded by National Institutes of Health · 2006 - 2012

Relationship of Depression to SCD Severity, Health Care Utilization and QoL

ResearchCo Investigator · Awarded by Agency for Healthcare Research and Quality · 2008 - 2011

Pulmonary Hypertension in SCD

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2005 - 2011

The Genomic Analysis of Erythrocyte microRNA in Sickle Cell Diseases

ResearchCo Investigator · Awarded by National Institutes of Health · 2008 - 2011

Duke-UNC Sickle Cell Disease Clinical Research Network

ResearchPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2006 - 2011

Outcome Modifying Genes in Sickle Cell Diseases

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2008

Activation of Sickle Red Cell Adhesion

ResearchMentor · Awarded by National Institutes of Health · 2003 - 2007

Adrenergic Receptor Variants and RBC Adhesion in SCD

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2004 - 2007

Minority Invest Post-Bacc Res. Supp. - T Jackson

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2006

Factors Involved in B-CAM/LU-Mediated Adhesion

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1999 - 2003

Sickle Cell Adhesion

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 2003

Transfusion Medicine And Related Areas

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1975 - 1999

Molecular Targets Of The In Lu Gene

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1987 - 1997

Molecular Targets Of The In(Lu) Gene

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1997

Molecular Targets Of The In (Lu) Gene

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1987 - 1997

Transfusion Medicine And Related Areas

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1975 - 1996

Transfusion Medicine And Related Areas

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1975 - 1996

Phosphatidylinositol-Anchored Blood Group Antigens

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1994 - 1995

Erythrocyte Protein Antigens Regulated By In-Lu

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1993

Erythrocyte Protein Antigens Regulated By In(Lu)

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1993

Erythrocyte Protein Antigens Regulated By In(Lu)

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1993

Erythrocyte Blood Group Antigens Regulated By In(Lu)

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1986 - 1988

Erythrocyte Blood Group Antigens Regulated By In (Lu)

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1985 - 1987

External Relationships


  • GLG
  • Guidepoint Global
  • Novartis
  • Pfizer Inc.

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.